The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial)
Open accessAbstract
Introduction: It remains unclear which surgery or radiofrequency ablation (RFA) is the more effective treatment for small hepatocellular carcinoma (HCC). We aimed to compare survival between patients undergoing surgery (surgery group) and patients undergoing RFA (RFA group). Methods: We conducted a randomized controlled trial involving 49 institutions in Japan. Patients with Child-Pugh scores ≤7, largest HCC diameter ≤3 cm, and ≤3 HCC nodules were considered eligible. The co-primary endpoints were recurrence-free survival (RFS) and overall survival (OS). The current study reports the final result of RFS, and the follow-up of OS is still ongoing. Results: During 2009–2015, 308 patients were registered. After excluding ineligible patients, the surgery and RFA groups included 150 and 151 patients, respectively. Baseline factors did not differ significantly between the groups. In both groups, 90% of patients had solitary HCC. The median largest HCC diameter was 1.8 cm (interquartile range [IQR], 1.5–2.2 cm) in the surgery group and 1.8 cm (IQR, 1.5–2.3 cm) in the RFA group. The median procedure duration (274 vs. 40 min, p < 0.01) and the median duration of hospital stay (17 days vs. 10 days, p < 0.01) were longer in the surgery group than in the RFA group. RFS did not differ significantly between the groups as the median RFS was 3.5 (95% confidence interval [CI], 2.6–5.1) years in the surgery group and 3.0 (95% CI, 2.4–5.6) years in the RFA group (hazard ratio, 0.92; 95% CI, 0.67–1.25; p = 0.58). Discussion/Conclusion: Our study did not show which surgery or RFA is the better treatment option for small HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cited by
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Self-citationHasegawa, K., Takemura, N., Yamashita, T., Watadani, T., Kaibori, M., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Aikata, H., et al. (2023) · Hepatology Research · doi:10.1111/hepr.13892 · Cited by 296
Self-citationPresent and future of metal nanoparticles in tumor ablation therapy
Lou, W., Xie, L., Xu, L., Xu, M., Xu, F., Zhao, Q., & Jiang, T. (2023) · Nanoscale · doi:10.1039/d3nr04362b · Cited by 33
Metadata
- Authors
- Takayama, T., Hasegawa, K., Izumi, N., Kudo, M., Shimada, M., Yamanaka, N., Inomata, M., Kaneko, S., Nakayama, H., Kawaguchi, Y., Kashiwabara, K., Tateishi, R., Shiina, S., Koike, K., Matsuyama, Y., Omata, M., Makuuchi, M., & Kokudo, N.
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2021-12-29
- Volume
- 11
- Issue
- 3
- Pages
- 209-218
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- OpenAlex
- W4200010849
- Cited by
- 207
- References
- 1
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial). https://app.cochat.ai/papers/10.1159/000521665
- The paper
- Takayama, T., Hasegawa, K., Izumi, N., Kudo, M., Shimada, M., Yamanaka, N., Inomata, M., Kaneko, S., Nakayama, H., Kawaguchi, Y., Kashiwabara, K., Tateishi, R., Shiina, S., Koike, K., Matsuyama, Y., Omata, M., Makuuchi, M., & Kokudo, N. (2022). Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial). Liver Cancer. https://doi.org/10.1159/000521665
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.